Actively Recruiting
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-09-08
2800
Participants Needed
1
Research Sites
224 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.
CONDITIONS
Official Title
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Confirmed cerebral infarction (stroke) by MRI or CT after stabilization or documented TIA with specific symptoms and carotid or intracranial stenosis treated or present
- Documented atherosclerotic stenosis of carotid, cerebral arteries, or aortic arch plaque as defined by imaging reports
- No current indication for colchicine treatment (such as gout or Mediterranean fever)
- Indicated for long-term antiplatelet therapy without oral anticoagulant indication
- Rankin score less than or equal to 4
- Fully informed and signed informed consent
- Possession of a social security number
- Medical examination prior to participation
- Use of highly effective contraception if of childbearing potential
- Pregnancy test for women of childbearing potential
You will not qualify if you...
- Need for colchicine treatment (e.g., gout, Mediterranean fever)
- Allergic reactions to ticagrelor or colchicine or their components
- Major digestive disorders such as chronic diarrhea or active inflammatory bowel disease
- Immunosuppression or medullary aplasia
- Active chronic inflammatory disease, infection, or progressing cancer
- Hemodynamic instability requiring prolonged support
- Recent severe sepsis or acute severe illnesses
- Chronic corticosteroid or NSAID treatment over 6 months or repeated high doses
- Planned use of strong CYP3A4 inhibitors or substrates that cannot be stopped
- Stroke or TIA caused by arterial dissection or cardiac embolism without atherosclerosis
- Indication for long-term oral anticoagulant treatment
- Symptomatic hemorrhagic stroke
- Active pathological bleeding
- Uncontrolled high blood pressure
- Inability to attend follow-up visits or expected poor compliance
- Intercurrent diseases interfering with study evaluation
- Anticipated pregnancy or breastfeeding
- Participation in other experimental pharmacotherapy affecting study drugs
- Leukopenia below 3000/μl
- Severe kidney impairment (creatinine clearance below 30 ml/min)
- Severe liver impairment
- Use of treatments contraindicated with colchicine or ticagrelor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
URC Lariboisière-Fernand Widal-Saint Louis
Paris, Paris, France, 75010
Actively Recruiting
Research Team
P
Pierre Amarenco, Pr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here